CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,605 enrolled
Drug / intervention
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01249027
NCT01249027N/ACompleted
CompareCT.gov

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

Abbott Medical Devices·observational·Posted Nov 29, 2010·Updated Mar 1, 2019

In Brief

An observational study evaluating XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) for Angioplasty and 8 related conditions. Completed, enrolled 2,605 participants across 1 site.

Detailed Summary

This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: * Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use * Evaluate patient compliance to dual antiplatelet therapy (DAPT)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAngioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 29, 2010
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 15.6 years ago

Interventions

XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)device

Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.